Neurogene appoints Christy Shafer as CCO, Christine Mikail to Board

Neurogene Inc.

Christy Shafer joins as CCO; previously SVP/GM at Avidity Biosciences and CCO at Marinus Pharmaceuticals.
Shafer will lead commercial strategy and launch readiness for NGN-401 gene therapy for Rett syndrome.
Christine Mikail, President and CFO, appointed to Board as Class II director through 2028 annual meeting.
Mikail brings expertise in strategy, finance, and corporate development; no additional compensation for board role.
Appointments position Neurogene for next phase of growth as it advances NGN-401 toward potential launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.